Strengthening Europe’s readiness for emerging infectious threats
The hantavirus outbreak on a transatlantic cruise vividly illustrates how quickly an unusual epidemic can arise in a confined, mobile setting and challenge existing response systems. PROACT EU-Response is designed for exactly that; to make Europe ready for this kind of unexpected emergency, by turning preparedness from an ad hoc reaction into a standing capability.
From surprise events to anticipatory systems
A cruise ship moving from Ushuaia to Cape Verde concentrates hundreds of people in a closed environment, with potential exposure to a rare rodent-borne pathogen and limited on‑board diagnostics or specialist care. Even if the public health risk to Europe is assessed as low, the event triggers complex questions about surveillance, triage, evacuation, communication, and research priorities that cannot be improvised mid‑crisis.
The COVID‑19 experience showed that waiting for a crisis before organizing trials, sites, and governance leads to delays in generating evidence on therapeutics and diagnostics. This is even more critical for rare or emerging infections like hantavirus, where there is no specific antiviral treatment and supportive intensive care is the main option.
What PROACT EU Response builds
PROACT EU‑Response and expands a pan‑European network for in hospitalised patients. It builds on the EU‑Response project and its large adaptive trials (e.g. DisCoVeRy, EU‑SolidAct) :
- A stable network of around 80 clinical trial sites in 21 European countries, ready to pivot rapidly when a new threat emerges.
- A common adaptive platform trial (EU‑SyndAct) that can quickly add or drop treatment arms as data accrue, instead of launching separate trials from scratch for each pathogen.
- Integrated governance, data infrastructure, and engagement with civil society so that research questions, consent, and communication are aligned with societal expectations.
By investing in this infrastructure before crises occur, PROACT EU‑Response shortens the time from “unusual cluster detected” to “robust evidence on what works” across Europe and beyond.
How this answers future epidemic needs
Events like a hantavirus outbreak at sea raise three broader needs: speed, coordination, and equity of access to evidence‑based care. PROACT EU‑Response addresses these by:
- Allowing rapid activation of multi‑country therapeutic and diagnostic trials as soon as cases are confirmed, rather than after months of set‑up.
- Providing harmonised protocols and data collection standards so results from patients in different countries and settings (including evacuated passengers) can be combined and analysed in near real time thereby offering the opportunity to get effective treatments and rapid diagnostics out in the public domain quickly
- Ensuring that patients affected by emerging infections, whether in large urban hospitals or smaller centres receiving evacuees, can be offered participation in high‑quality research and an opportunity to get early access to treatment, in the context of a clinical trial, with appropriate safeguards.
In practical terms, the same adaptive platform that tests antivirals for respiratory viruses today can be reconfigured to evaluate supportive strategies, novel therapeutics, or diagnostic algorithms for a hantavirus‑like threat tomorrow. This turns each crisis into an opportunity to learn faster, reduce mortality and morbidity, and strengthen health‑system resilience over time.
